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Background: The majority of in vitro studies of medically relevant biofilms involve the development of biofilm on an
inanimate solid surface. However, infection in vivo consists of biofilm growth on, or suspended within, the semi-solid
matrix of the tissue, whereby current models do not effectively simulate the nature of the in vivo environment. This
paper describes development of an in vitro method for culturing wound associated microorganisms in a system that
combines a semi-solid collagen gel matrix with continuous flow of simulated wound fluid. This enables culture of
wound associated reproducible steady state biofilms under conditions that more closely simulate the dynamic wound
environment. To demonstrate the use of this model the antimicrobial kinetics of ceftazidime, against both mature and
developing Pseudomonas aeruginosa biofilms, was assessed. In addition, we have shown the potential application of
this model system for investigating microbial metabolomics by employing selected ion flow tube mass spectrometry
(SIFT-MS) to monitor ammonia and hydrogen cyanide production by Pseudomonas aeruginosa biofilms in real-time.
Results: The collagen wound biofilm model facilitates growth of steady-state reproducible Pseudomonas aeruginosa
biofilms under wound like conditions. A maximum biofilm density of 1010 cfu slide− 1 was achieved by 30 h of
continuous culture and maintained throughout the remainder of the experiment. Treatment with ceftazidime at a
clinically relevant dose resulted in a 1.2–1.6 log reduction in biofilm density at 72 h compared to untreated controls.
Treatment resulted in loss of complex biofilm architecture and morphological changes to bacterial cells, visualised
using confocal microscopy. When monitoring the biofilms using SIFT-MS, ammonia and hydrogen cyanide levels
peaked at 12 h at 2273 ppb (±826.4) and 138 ppb (±49.1) respectively and were detectable throughout
experimentation.
Conclusions: The collagen wound biofilm model has been developed to facilitate growth of reproducible
biofilms under wound-like conditions. We have successfully used this method to: (1) evaluate antimicrobial
efficacy and kinetics, clearly demonstrating the development of antimicrobial tolerance in biofilm cultures; (2)
characterise volatile metabolite production by P. aeruginosa biofilms, demonstrating the potential use of this
method in metabolomics studies.
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It is widely accepted that bacteria commonly exist in ses-
sile communities known as biofilms, rather than as indi-
vidual free swimming cells [1]. Biofilms are implicated in
a range of clinically relevant infections including lung in-
fection in cystic fibrosis, endocarditis, osteomyelitis,
acute burn infection and chronic wound infection [2, 3].
Established biofilms are typically highly tolerant to anti-
microbials and the host immune response [4]. The
extracellular polymeric substance (EPS) protects bacter-
ial cells within the biofilm by providing a physical barrier
which decreases penetration of antimicrobials and agents
of the host immune system [5, 6]. Furthermore, this bio-
film phenotype is often coupled with a reduced meta-
bolic activity and growth rate, typically seen within the
interior of biofilm communities, which reduces the sus-
ceptibility to those antimicrobials which target such pro-
cesses [7, 8]. A recent review of clinical studies
conducted between 2008 and 2015, concluded that bio-
films were present in 78.2% of chronic wounds [9], indi-
cating the important role that biofilms play in the
development of a chronic wound state. Detailed investi-
gation of the distribution of infecting organisms within
chronically infected wounds has demonstrated differ-
ences in the depth of microbial biofilm aggregates
embedded within the wound bed [10–13]. For example,
one study demonstrated the presence of Pseudomonas
aeruginosa micro colonies embedded deeper within the
wound bed than those of Staphylococcus aureus which
were found closer to the wound surface [12]. The role of
biofilms in the infection of acute wounds has been less
well characterized, however biofilm formation has been
observed in animal models of acute burn wound and
surgical site infection [11, 14, 15].
In vitro studies of biofilms employ one of two ap-
proaches; a closed multi-well plate based model, or
an open flow system with the continuous perfusion of
nutrient into the model and waste products continu-
ously exiting the system [16]. Both of these ap-
proaches often involve the development of biofilms
on solid surfaces, usually plastic or glass. Microbial
infection in vivo consists of biofilm growth on the
surface of, or suspended within, the semi-solid matrix
of the tissue, unless adhered to an implanted medical
device or catheter [17]. Collagen based gel matrices
have been used as a substratum for culturing biofilms
in vitro, in an attempt to closely simulate the semi-
solid nature of the wound [18–22]. However, a limita-
tion of these closed systems, is that they do not simu-
late the replacement of nutrients and moisture that
occur within the wound bed due to the production of
exudate, which provides the continuous flux of nutri-
ents available to the biofilm during formation and
growth [23, 24].To further our understanding and knowledge of
wound infection processes, a wound biofilm model is re-
quired that better simulates the wound environment.
This could be achieved by the combination of a continu-
ous flow biofilm model system with a semi-solid
‘wound-like’ growth substrate and a more representative
growth media. We describe an in vitro method for cul-
turing wound associated microorganisms within a colla-
gen wound biofilm model, combining a drip flow reactor
system (Biosurface technologies, MZ, USA) with a three-
dimensional type I collagen gel growth matrix and con-
tinuous perfusion of a previously developed simulated
wound fluid (SWF) [18, 21, 25, 26]. To demonstrate the
application of this method, it has been utilized to study
the antimicrobial kinetics of ceftazidime, when used to
treat P. aeruginosa biofilms during early or late stage de-
velopment. P. aeruginosa is among the most commonly
isolated pathogens from both chronic and acute burn
wound infections [27, 28] and biofilms have been shown
to rapidly result in systemic infection in a mouse model
of acute burn infection [14]. Ceftazidime is considered a
first choice antipseudomonal antibiotic [29, 30] for treat-
ment when there is a high risk of systemic infection
developing from an infected wound. To further demon-
strate the potential of this novel model, a preliminary in-
vestigation of microbial metabolomics in relation to
microbial biofilm development was undertaken using se-
lected ion flow tube mass spectrometry (SIFT-MS). Am-
monia and hydrogen cyanide have previously been
reported as important potential diagnostic metabolites
detected in the headspace of P. aeruginosa liquid cul-
tures in vitro [31], and in P. aeruginosa infections
in vivo [32, 33], through analysis of the exhaled breath
of cystic fibrosis patients. Hydrogen cyanide is generated
through decarboxylation of the amino acid glycine by
the membrane bound hydrogen cyanide synthase en-
zyme [34], ammonia is produced by the metabolism of
nitrogen containing compounds including hydrogen
cyanide [31]. Real-time monitoring of bacterial volatile
metabolites, has gained momentum in recent years as a
potential rapid diagnostic tool [32, 35–41]. The novel
collagen wound biofilm model reported here, allows the
development of this diagnostic approach in the context
of wound infection. For example by the detection of
volatile metabolite profiles emitted by biofilm cultures,
produced under conditions which closely simulate the
wound environment.
Results
Characterization of the in vitro collagen perfusion wound
biofilm model
The un-inoculated collagen growth matrix, which poly-
merizes at 37 °C to form a hydrated three-dimensional
semi-solid gel layer on the surface of the microscope
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croscopy (SEM). The fixation and dehydration process
required for preparation of samples for SEM results in
collapse of the three-dimensional structure, although the
mesh-like network of long collagen fibers remains clearly
visible (Fig. 1a). SEM imaging of a P. aeruginosa biofilm
cultured on the collagen gel growth matrix shows a
dense layer of microbial cells masking the collagen fibers
below. Multiple layers of P. aeruginosa are visible, as is
the dehydrated biofilm extracellular polymeric sub-
stances (EPS) which can be see connecting adjacent bac-
terial cells (Fig. 1b).
The developed novel collagen wound biofilm model
system supports growth of reproducible P. aeruginosa
biofilms during both early and late stage development. A
maximum biofilm density of 1010 cfu slide− 1 (dictated by
the experimental conditions) was achieved by 30 h of
continuous culture.
Figure 2 shows growth of P. aeruginosa NCIMB 10548
biofilms over 72 h at 33 °C in the collagen wound biofilm
model. The maximum density was maintained at an ap-
proximately steady-state of 6.0 × 1010–8.0 × 1010 cfu
slide− 1, from 30 h until the end of experimentation (72Fig. 1 Scanning electron micrographs of a collagen gel and b
Pseudomonas aeruginosa NCIMB 10548 biofilm cultured on a
collagen gel matrixh) and equates to a microbial burden per gram of colla-
gen of 4 × 1010–5.3 × 1010 cfu g− 1. In addition to sam-
pling for enumeration, biofilms were sampled after 6, 12,
24 and 48 h of continuous culture for confocal micros-
copy, to determine the structural arrangement of bacter-
ial cells and biofilm architecture during growth and
development (Fig. 3). The biofilm sampled at 6 h con-
sisted of sparsely arranged P. aeruginosa cells with some
small aggregates (Fig. 3a), whereas at 12 h the cell dens-
ity had increased and some larger aggregates were visible
(Fig. 3b). At 24 h the density of the bacterial cells had
again increased, in line with the enumeration data
(Fig. 2), whereby more complex structural formations
and the development of surface protrusions and chan-
nels can be seen (Fig. 3c). At 48 h, the biofilm architec-
ture within the maturing biofilm shows evidence of
increased variability in surface topography, as described
within other biofilm studies [42–44].
Application of the collagen wound biofilm model for
studying antimicrobial kinetics
To demonstrate the application of this novel method the
collagen wound biofilm model was used to investigate
the antimicrobial activity of antibiotic therapy against
biofilms at a clinically relevant dose. To confirm suscep-
tibility of P. aeruginosa NCIMB 10548 to ceftazidime,
planktonic minimum inhibitory concentration (MIC)
values were determined (n = 3) using a standard microdi-
lution multi-well plate assay [45]; the MIC was deter-
mined to be 2.0 mg L− 1. The clinical breakpoint for
ceftazidime against P. aeruginosa according to the Euro-
pean Committee on Antimicrobial Susceptibility testing
is 8 mg L− 1 [46]. Hence, the MIC of 2.0 mg L− 1, indi-
cates that this strain is considered sensitive to ceftazi-
dime. Once susceptibility of the strain was confirmed
the efficacy of ceftazidime against P. aeruginosa biofilms
was investigated using the collagen wound biofilm
model. A target serum concentration of 40 mg L− 1 for
continuous infusion of ceftazidime is recommended for
effective treatment of P. aeruginosa infections in vivo
[29, 30, 47], hence this drug concentration was selected
to challenge the P. aeruginosa biofilms in the collagen
wound biofilm model. Figure 4 shows the change in bio-
film density resulting from ceftazidime treatment at 40
mg L− 1, compared to normal growth conditions. Treat-
ment was started after either 6 h or 30 h of continuous
culture, to enable comparison of treatment efficacy on
the early stage of biofilm formation and on established
steady state maturing P. aeruginosa biofilms. When
treatment was initiated at the early stage of biofilm
formation, the total biofilm density decreased for the
first 12 h of treatment to approximately 5 × 108 cfu
slide− 1 (1.63 log reduction compared to untreated
controls; p < 0.01). The biofilm density remained
Fig. 2 Pseudomonas aeruginosa NCIMB 10548 biofilm density when grown in the collagen wound biofilm model system over 72 h at 33 °C
(n = 3 per time point; mean ± SD). An approximately steady-state at 6.0 × 1010–8.0 × 1010 cfu slide− 1 was maintained from 30 h to the end
of experimentation at 72 h
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over the following 24 h to reach a density of 2 × 109
cfu slide− 1. This density was maintained until the
final sampling time (72 h of continuous culture)
resulting in a significant 1.6 log reduction compared
to untreated controls (p < 0.05) at the end of experi-
mentation. During treatment of established maturing
biofilms, the biofilm density gradually decreased
ultimately resulting in a mean biofilm density of
5.5 × 109 cfu slide− 1 at 72 h (a significant 1.2 log re-
duction compared to the untreated control; p < 0.05).
When comparing treatment initiated at the early stage
of biofilm development or on established maturing
biofilms, although both treatment regimens exhibited
a significant antimicrobial effect, there was no signifi-
cant difference in biofilm density between these treat-
ment groups after 72 h of continuous culture.
Figure 5 shows confocal scanning laser micrographs of
P. aeruginosa biofilms treated with 40mg L− 1 ceftazi-
dime. Samples for both treatment regimens were imaged
after both 18 h and 42 h of exposure to the ceftazidime;
this corresponds to a total culture time of 24 h and 48 h
for the samples where antibiotic treatment was started
at the early stage of biofilm formation, and 48 h and 72 h
total culture time for the samples where treatment was
started on established biofilms. Samples imaged follow-
ing 18 h of exposure to ceftazidime at 40 mg L− 1 (Fig. 5;
a1 & b1) both show some elongation of P. aeruginosa
cells. Within the confocal z-stack, it was observed that
this was most pronounced in the bacterial cells nearest
to the surface of the biofilms, whereas cells deeper
within the biofilm were morphologically more similar tothe untreated sample (Fig. 3). After 42 h of antibiotic ex-
posure, it was observed that there was a high proportion
of elongated bacterial cells (Fig. 5; a2 & b2). The biofilm
appears less densely packed with clear spaces between the
tangles of filamentous cells, compared to untreated bio-
films shown in Fig. 3. By comparing untreated (Fig. 3c)
and treatment of early stage biofilms (Fig. 5; a1 and a2) it
is clear that the ceftazidime treatment prevents the devel-
opment of complex biofilm architecture. In addition,
when comparing untreated (Fig. 3d) and the treatment of
established biofilms (Fig. 5; b1), it is evident that
ceftazidime treatment has resulted in the collapse of the
characteristic three-dimensional biofilm structure. Dem-
onstrating the effect of ceftazidime on the complex biofilm
structure, as well as the morphology of individual bacterial
cells.
Application of the collagen wound biofilm model for
studying biofilm metabolomics
Selected ion flow tube mass spectrometry was used to
monitor headspace concentrations of volatile metabolites
in real-time. Detection of ammonia and hydrogen
cyanide was chosen to demonstrate the capability of ana-
lyzing volatile metabolites produced by developing P.
aeruginosa biofilms in the collagen wound biofilm
model. Biofilm headspace was sampled and analyzed
repeatedly using the SIFT-MS instrument throughout
the 72 h duration of biofilm growth and development.
Figure 6 shows the concentration of ammonia and
hydrogen cyanide respectively, detected in the headspace
of P. aeruginosa biofilm cultures. The concentration of
both compounds (ppb) had an initial peak at 12 h, with a
Fig. 3 Confocal scanning laser micrographs of Pseudomonas aeruginosa NCIMB 10548 biofilms grown in the collagen wound biofilm model.
Sampled after a 6 h, b 12 h, c 24 h and d 48 h of continuous culture. Main panels show XY plane, right panels show YZ slice and bottom panels
show XZ slice. Green Syto 9 staining indicates live bacterial cells and red propidium iodide staining indicates dead bacterial cells
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ppb for hydrogen cyanide. The hydrogen cyanide con-
centration then dropped to a mean concentration of 81
ppb at 18 h before again increasing gradually to a peak
of 191 ppb. The concentration of ammonia also dropped,
with a mean concentration of 797 ppb recorded at 21 h
and then continued to fluctuate between approximately
600 and 1200 ppb for the remaining duration of analysis.
The concentration of both ammonia and hydrogen cyan-
ide remained at levels detectable using SIFT-MS
throughout the duration of growth and development of
P. aeruginosa biofilms within the collagen wound biofilm
model.
Discussion
The dermis of human skin is primarily composed of the
protein collagen [48]. Type I collagen is the most abun-
dant type found in human skin and is distributed
throughout all layers of the dermis [49]. We have suc-
cessfully developed a dynamic collagen wound biofilm
model utilising a three-dimensional collagen gel growthmatrix comprised of a mesh of polymerized type I colla-
gen fibres (Fig. 1), to simulate the semi-solid wound en-
vironment found in vivo. Continuous perfusion with
SWF provides replacement of moisture and nutrients,
and removal of waste products, that would be provided
by the flow of exudate within infected wounds [50]. The
simulated wound fluid provides a similar range of nutri-
ents as exudate, a high protein fluid that leaks from the
blood vessels in response to inflammation associated
with wound healing processes [51]. Biochemical analysis
of wound fluid has shown that a similar range of constit-
uents are present when compared to serum, with con-
centrations in would fluid at lower levels than in serum
for the majority of components [52]. This suggests use
of a simulated wound fluid comprised of 50% serum will
provide a suitable range of nutrients, many of which will
be at biologically relevant concentrations. We have vali-
dated the growth of P. aeruginosa with this method and
demonstrated that it enables culture of reproducible
steady state biofilms at a density greater than that con-
sidered to be the critical threshold of clinically relevant
Fig. 4 Treatment of Pseudomonas aeruginosa NCIMB 10548 biofilms with ceftazidime at 40mg L-1, showing antimicrobial kinetics when used
against established maturing biofilms (30 h) and early stage biofilms (6 h), compared to untreated controls. (n = 3 per time point per condition;
mean ± SD). Arrows indicate treatment start times. Treatment started at 30 h resulted in a 1.2 log reduction in total biofilm density at 72 h,
compared to untreated controls (p < 0.05). Treatment started at 6 h resulted in a 1.6 log reduction in total biofilm density at 72 h, compared to
untreated controls (p < 0.01). No significant difference (p > 0.05) between treated groups at 72 h
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sidered the critical threshold indicative of clinically rele-
vant wound infection [53–55], with a bioburden of
between 109 and 1011 cfu g− 1 tissue identified from in-
fected wounds with the heaviest bacterial loads [54, 56].
Hence, the density achieved within the collagen wound
biofilm model represents an appropriate bacterial load,
reflective of a challenging clinical situation for assessing
antimicrobial efficacy. Characterisation of the collagen
wound biofilm model has focused on cultivation of P.
aeruginosa NCIMB 10548, a commercially available
strain originally isolated from an infected wound. How-
ever, future studies could apply the collagen wound bio-
film model to investigate the growth rate and
susceptibility of clinical isolates of P. aeruginosa and
other wound associated species.
MIC assays are routinely used clinically to determine
the susceptibility of bacterial isolates to the antibiotic
treatments available. However, as demonstrated within
this study, this is unlikely to predict the effectiveness of
antimicrobials against biofilms and hence their thera-
peutic effectiveness against biofilm infections. To dem-
onstrate the application of this model system for
evaluating the efficacy and kill kinetics of antimicrobial
agents, both developing and established P. aeruginosa
biofilms were challenged with the cephalosporin anti-
biotic ceftazidime. There was no significant difference
(p > 0.05) in the final biofilm density after 72 h ofcontinuous culture, when comparing the two treatment
start times. Both treatment strategies resulted in a sig-
nificant reduction of total biofilm density at 72 h com-
pared to the untreated biofilm. Although a statistically
significant reduction in viable P. aeruginosa biofilm
density was demonstrated, the remaining mean biofilm
density of 2.2 × 109 and 5.5 × 109 cfu slide− 1 for the two
treatment regimens equates to 1.5 × 109 and 3.6 × 109
cfu g− 1 of collagen ‘tissue’ respectively. This density re-
mains vastly in excess of the 105 cfu g− 1 of ‘tissue’, used
as the critical threshold indicative of invasive infection
and risk of sepsis in studies of quantitative microbio-
logical analysis of wound biopsy samples [54, 55]. It has
previously been reported that there are differences be-
tween the planktonic MIC and the concentration of cef-
tazidime (and a range of other antimicrobials) required
to eradicate biofilms, with concentrations 1000-fold
greater than the MIC unable to eradicate P. aeruginosa
biofilms within a static model [57]. Using the collagen
wound biofilm model, we have shown the time course of
the development of such tolerance for the first time
under wound like conditions in vitro, and visualized the
effect of drug treatment on the biofilm structure. Ceftaz-
idime treatment resulted in distinct morphological
changes in the general biofilm architecture as well as the
discrete bacterial cells. This elongation response by P.
aeruginosa to β-lactam antibiotics, including ceftazidime,
has been described previously and was observed to result
Fig. 5 Confocal scanning laser micrographs of Pseudomonas aeruginosa NCIMB 10548 biofilms treated with ceftazidime at 40 mg L− 1. Top panels,
treatment initiated at 6 h (early stage of biofilm formation); (a1) sample imaged following 18 h exposure to treatment and (a2) 42 h exposure to
treatment. Bottom panels, treatment initiated at 30 h (maturing biofilm); (b1) biofilm sampled following 18 h exposure to treatment (48 h) and
(b2) 42 h exposure to treatment. Main panels show XY plane, right panels show YZ slice and bottom panels show XZ slice. Green Syto 9 staining
indicates live bacterial cells and red propidium iodide staining indicates dead bacterial cells
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culture [58]. It has been determined that inhibition of
penicillin binding protein 3 (PBP3) by β-lactam antibi-
otics is responsible for causing filamentation in P. aeru-
ginosa. This has been demonstrated by deletion of the
gene required for PBP3 expression and comparison of
the resulting morphological changes to those seen when
P. aeruginosa was exposed to sub-lethal concentrations
of β-lactam antibiotics [59]. This phenomena has also
been observed in response to β-lactam exposure in
Escherichia coli [60], where cell elongation is reported to
be the first of a four step process leading to eventual cell
lysis.
The developed method facilitates investigation of mi-
crobial metabolomics, including volatile metabolites pro-
duced by bacterial species associated with causing
clinically relevant wound infection [38]. Selected ion
flow tube mass spectrometry was used for real-time de-
tection of the volatile compounds ammonia andhydrogen cyanide in the collagen wound biofilm model.
Monitoring of volatile compounds during biofilm growth
and development from a perfusion biofilm model has
not been reported previously. In the collagen wound bio-
film model, the concentration of both compounds in-
creased for approximately the first 12 h, corresponding
to the most rapid increase in biofilm density. Subse-
quently, the concentration of both compounds decreased
from 12 to 24 h. Investigations of real-time production
of hydrogen cyanide and ammonia from reference
strains and clinical isolates of P. aeruginosa in liquid cul-
ture indicated a peak in hydrogen cyanide concentration
at the transition to stationary phase only [31]. Interest-
ingly, the drop in concentration of both volatile com-
pounds between 12 and 24 h, corresponds with distinct
changes in the arrangement of bacterial cells and devel-
opment of the biofilm structures observed by confocal
microscopy (Fig. 3), as well as a decrease in the rate at
which the biofilm density was increasing. When the
Fig. 6 Detection of volatile metabolites ammonia and hydrogen cyanide during growth and development of Pseudomonas aeruginosa NCIMB
10548 biofilms in the collagen wound biofilm model. a Ammonia concentration (ppb) detected in the headspace of P. aeruginosa biofilms for 72
h (black); left Y axis (n = 4; mean ± SD). Mean biofilm density over 72 h (grey): right Y axis. b Hydrogen cyanide concentration (ppb) detected in
the headspace of P. aeruginosa biofilms for 72 h (black); left Y axis ( = 4; mean ± SD). Mean biofilm density over 72 h (grey): right Y axis
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biofilm model (≥30 h), the concentration of ammonia
also stabilized. In contrast, the concentration of hydro-
gen cyanide continued to gradually increase throughout
the remaining analysis time. Again, this is in contrast to
that reportedly seen in planktonic culture [31], whereby
production of hydrogen cyanide was maintained for only
1 to 4 h after the initial peak. These differences may re-
sult from changes in the metabolic activity associated
with the biofilm mode of growth, coupled with the con-
tinuous supply of substrates for metabolism and removal
of waste products within our model, which is more rep-
resentative of the in vivo environment. The concentra-
tion of both hydrogen cyanide and ammonia remained
at levels detectable by SIFT-MS throughout the 72 h
sampling time, confirming the potential application of
detection of these compounds as markers of P.aeruginosa presence that could usefully be exploited
through development of rapid point of care diagnostic
devices.
Conclusions
The collagen wound biofilm model has been successfully
developed and evaluated for the growth of steady-state
biofilms under wound like conditions. We have demon-
strated the potential of the collagen wound biofilm
model for use in metabolomics studies, by characterising
volatile metabolite production from P. aeruginosa, a clin-
ically relevant pathogen associated with wound infection.
Furthermore, the collagen wound biofilm model not
only demonstrates the failure of biofilm eradication
using a clinically relevant ceftazidime concentration, but
also allows the evaluation of antimicrobial kinetics,
clearly demonstrating the development of tolerance in
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early and late stage development.
Methods
Preparation and maintenance of bacterial cultures
P. aeruginosa (NCIMB 10548) was maintained on beads
(Pro-Lab Diagnostics, Birkenhead, UK) at − 80 °C, resus-
citated as required on Tryptone Soya Agar (TSA) (Oxoid
Ltd. Basingstoke, UK) and incubated aerobically at 37 °C.
Working cultures were stored on sealed plates at 4 °C.
Collagen coating of glass slide coupons
The collagen gel matrix was prepared based on the
method described by Werthén et al. (2010) by preparing
a collagen solution (2.0 mgmL− 1) in simulated wound
fluid (SWF) [18, 21, 25, 26]. The SWF comprised of
equal volumes of fetal bovine serum (Life Technologies
Limited, Paisley, UK) and a solution of 0.1% bacterio-
logical peptone (Oxoid Ltd. Basingstoke, UK) and 0.85%
sodium chloride (Fisher Scientific Limited, Loughbor-
ough, UK). High concentration collagen (type I) from rat
tail in 0.02M Acetic Acid (Corning Incorporated, Wies-
baden, Germany) was neutralized to pH 7 with 1M so-
dium hydroxide according to manufacturer instructions
and diluted to the desired concentration with SWF. For
example, to prepare 10 mL of 2.0 mgmL− 1 collagen so-
lution in SWF from a collagen stock solution of 9.59 mg
mL− 1; 48 μL of ice cold sodium hydroxide was added to
7.866 mL of ice cold SWF and mixed. On ice, 2.086 mL
of ice cold collagen stock solution was then added and
the solution mixed gently. Sterile glass microscope slides
measuring 76 mm× 26mm were coated with 1.5 mL of
neutralized collagen solution (2.0 mgmL− 1), resulting in
a depth of 760 μm. Collagen coated slides were incu-
bated at 37 °C for 1 h to allow polymerization of the
three-dimensional collagen matrix.
Preparation of bacterial cultures
Overnight plate cultures (18–24 h) were used to prepare
a suspension of P. aeruginosa in 10 mL SWF, adjusted to
an OD620nm of 0.20, equivalent to 2 × 10
8 cfu mL− 1. One
milliliter of the test suspension was used to inoculate
each collagen coated microscope slide (individually
housed in sterile petri dishes) and incubated at 33 °C for
2 h to allow initial adherence of bacterial cells.
Growth of bacterial biofilms within the collagen wound
biofilm model
Following incubation, the inoculated slides were rinsed
gently three times with 1mL of sterile SWF to remove
planktonic cells, and carefully transferred to individual
channels within the drip flow reactor (Biosurface Tech-
nologies Corporation, Bozeman, MT, USA). Sterile sili-
cone tubing (3 mm ID) was used to connect a 500 mLDuran bottle containing the sterile SWF medium to the
miniert valve lid inlets via a 23 Gauge 1.25 in sterile
needle. Waste was collected in 250 mL Duran bottles
connected to the waste outlet ports using lengths of sterile
silicone tubing (8mm ID). The reactor was incubated at
33 °C to simulate average wound bed temperature [61] for
48–72 h at an angle of 10° to allow SWF to flow through
the individual chambers of the model system (Fig. 7). The
collagen wound biofilm model was continuously perfused
with SWF at a flow rate of 2mL hr.− 1 for the duration of
incubation to simulate the flow of a moderately exuding
wound (50mL over 24 h) [62].
Imaging of bacterial biofilms and collagen matrix
During preparation of collagen gel matrices for im-
aging experiments, a #1 glass cover slip measuring 18
mm × 18 mm was included between the microscope
slide and collagen gel layer. The inclusion of a cover-
slip facilitated the sampling of a suitable sized section
of the biofilm for microscopy. This was removed by
cutting the collagen around the cover slip with a be-
spoke square stainless steel cutter and lifting away
the coverslip supporting the biofilm sample with the
aid of a scalpel blade.
Scanning Electron microscopy (SEM)
Biofilm samples and an un-inoculated collagen gel con-
trol were fixed in 4% Glutaraldehyde (Sigma-Aldrich
Company Limited, Gillingham, UK) in a 0.1M phos-
phate buffer for 1 h at room temperature. This was
rinsed in phosphate buffered saline (PBS) and dehy-
drated with increasing concentrations of ethanol and
hexamethyldisilazane (Acros Organics, Geel, Belgium),
air dried in a fume hood, mounted and gold sputter
coated. A FEI Quanta 650 FEG scanning electron micro-
scope operating at 10 kV was used to examine the
samples.
Confocal scanning laser microscopy
Biofilm samples were stained using the FilmTracer
LIVE/DEAD Biofilm Viability Kit (Fisher Scientific
UK Limited, Loughborough, UK) according to manu-
facturer’s instructions: 3 μL each of Component A
(SYTO 9 green fluorescent nucleic acid stain 3.34 mM
in DMSO) and Component B (Propidium iodide 20
mM in DMSO) were added to 1 mL of sterile filtered
deionized water to prepare a working solution. Three
hundred microliters of the prepared staining solution
was gently added to the biofilm surface. Samples were
incubated at room temperature for 30 min in the
dark. Following incubation samples were rinsed gently
with sterile filtered deionized water to remove excess
stain and imaged using the × 40 oil objective of the
Leica DMi8 Inverted microscope with confocal
Fig. 7 In vitro collagen wound biofilm model, comprising a drip flow reactor set-up incorporating collagen coated slide coupons, showing
assembly with tubing connected to simulated wound fluid reservoir and waste collection
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nes, UK). Confocal Z-stack scans were exported to
Fiji [63] for image processing.
Enumeration of bacterial biofilms
Bacterial biofilms were sampled at 0, 3 and 6 h, then
every 6 h until 48 h and finally at 72 h. At each time
point a coated slide was aseptically removed from the
reactor and the entire collagen layer containing the
bacterial biofilm scraped into a 50 mL falcon tube
using a sterile L-shaped scraper, while rinsing with
3 × 1 mL PBS. Two milliliters of 500 μg mL− 1 collage-
nase solution (Life Technologies Limited, Paisley, UK)
was added to the tube, mixed and incubated at 37 °C
for 20 min and then mixed by vortexing and incu-
bated for a further 20 min. The resulting suspension
was disrupted by sonication in a water bath (Fisher-
brand FB11078, Fisher Scientific Limited, Loughbor-
ough, UK) at 35 kHz for 5 min. Collagenase solution
was washed from the bacterial cells; whereby the sus-
pension was centrifuged at 4000 x g, the supernatant
discarded and pellet re-suspended in 10 mL PBS a
total of two times. Bacterial density (cfu slide− 1) was
determined by serially diluting in PBS and spiral plat-
ing (Whitley Automated Spiral Plater, Don Whitley
Scientific Limited, Bingley, UK) on to TSA. Colonies
were counted after 24 h incubation at 37 °C.Antimicrobial susceptibility – broth microdilution
The antimicrobial susceptibility of P. aeruginosa
NCIMB 10548 to ceftazidime was tested based on the
broth microdilution method described by BS EN ISO
20776-1:2006 [45]. Ceftazidime was prepared at con-
centrations ranging from 256 mg L− 1 to 0.25 mg L− 1.
Fifty microliters of each antibiotic concentration and
a control of 0 mg L− 1 of ceftazidime were dispensed
in triplicate into wells of a 96 well multi-well plate.
Overnight plate cultures were used to prepare a stan-
dardized suspension (1 × 106 cfu mL− 1) of P. aerugi-
nosa NCIMB 10548 in 10 mL Muller-Hinton Broth
(MHB) (Oxoid Ltd. Basingstoke, UK). Fifty microliters
of the inoculum suspension were added to each of
the wells of the multi-well plate containing 50 μL of
MHB or MHB with ceftazidime. The resulting final
inoculum was approximately 5 × 105 cfu mL− 1 and
final ceftazidime concentrations ranged from 128 mg
L− 1 to 0.125 mg L− 1, plus antibiotic free controls.
Additionally, three wells were prepared containing
100 μL of MHB only as un-inoculated negative con-
trols. The multi-well plate was then incubated at
37 °C for 18 h. The inoculum suspension was serially
diluted and 100 μL spread plated on to TSA and
incubated at 37 °C overnight to confirm appropriate
inoculum preparation. Following incubation each well of
the plate was visually inspected to identify turbidity to
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controls. Agar plates were counted after 18–24 h to con-
firm inoculum density was within the required range.
Antimicrobial susceptibility – biofilms
Biofilm cultures were grown on collagen coated slides in
the drip flow reactor system as described above. Ceftazi-
dime treatment was started after either 6 h, when cul-
tures are at an early stage of biofilm development, or 30
h of continuous culture, when biofilms are established
and maturing. Residual SWF was drained via the tubing
and the media reservoir refilled with fresh SWF contain-
ing ceftazidime at 40 mg L− 1. Biofilms were sampled
periodically as described above to determine the effect of
ceftazidime treatment on biofilm density over time.
SIFT-MS analysis of bacterial biofilms
Volatile compounds were sampled from the headspace
of collagen wound biofilm cultures by connecting the
heated sample inlet of the selected ion flow tube mass
spectrometry (SIFT-MS) instrument (Voice200Ultra, Syft
Technologies, Christchurch, NZ) to the reactor channel
via a length of PEEK tubing. To connect the PEEK tub-
ing, bespoke modified biofilm reactor lids with an add-
itional valve port were used. The SIFT-MS instrument
was operated in selected ion mode (SIM) using the
H3O
+, NO+ and O2
+ reagent ions to quantify hydrogen
cyanide and ammonia concentrations in the biofilm
headspace throughout the 72 h growth and development
period.
Data analysis
Biofilm enumeration data were analyzed by performing
t-tests comparing specific time points of interest using
Graphpad Prism 7 (GraphPad Software Inc., California,
USA). SIFT-MS data for each independent P. aeruginosa
biofilm were extracted using MATLAB R2018a (The
MathWorks, Inc., Natick, Massachusetts, United States).
In order to remove signal noise from the data the mean
concentration of each compound was calculated for each
hour of analysis.
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